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ABSTRACT
Body fluid identification is an important aspect of forensic investigations because it
assists with the reconstruction of crime scenes and can refute and/or support witness statements.
Currently, there is no universal method for body fluid identification. Each body fluid has several
tests for its identification, both presumptive and confirmatory. A universal method for body fluid
identification that is sensitive, specific, efficient, and minimally destructive is necessary.
In recent years miRNAs have been heralded as novel biomarkers for the identification of
body fluids. Several research groups across the US and internationally have been formed to
determine which miRNAs are suitable for body fluid identification, however there has been little
agreement between them in their conclusions. With the advent of Next Generation Sequencing
(NGS), it is now possible to sequence all forensically relevant body fluids for both known and
novel miRNAs, with the expressed interest to identify panels of miRNAs for each body fluid.
The goal of this study was to determine if it was feasible to use NGS in the form of the
MiSeq FGx platform (Illumina) to determine a panel of miRNAs that are specific to forensically
relevant body fluids including venous blood, semen, saliva, vaginal fluid, and menstrual blood.
Subsequently, a panel of miRNAs was identified from previously published research that were
reported to have potential applications to forensic body fluid identification. Ultimately, it was the
goal of this study to determine if the chosen miRNAs were suitable for body fluid identification.
This was done using RT-qPCR, which is the preferred method of miRNA expression analysis.
It was determined that the MiSeq FGx was not an optimal NGS platform for this purpose,
as no miRNAs were identified. The RT-qPCR validation of the chosen miRNAs resulted in both
agreement and disagreement with previously published results, illustrating the need for more
extensive research to determine an appropriate panel of miRNAs for body fluid identification.
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CHAPTER 1: INTRODUCTION
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CHAPTER 1: INTRODUCTION

1.1
1.1.1

Forensic Body Fluid Identification
Introduction
The identification of forensically relevant body fluids including venous blood, menstrual

blood, semen, vaginal material, and saliva is an extremely important aspect of forensic
investigations. Some ask whether this identification is necessary when obtaining a DNA profile
from body fluids is possible and seems more useful. The identification of the body fluid is just as
important as obtaining a DNA profile because the correct identification of a body fluid can help
reconstruct the events that took place and can potentially corroborate or refute witness
statements. Body fluid identification is very important in all forensic investigations but can be
especially important in sexual assault investigations. For example, if a condom was worn by the
perpetrator during an assault, the correct identification of the body fluids on the outside of the
condom can be very helpful to the case. If the victim claims there was forced vaginal intercourse,
while the suspect claims that there was only voluntary oral intercourse, the identification of the
body fluid on the outside of the condom could be helpful in determining which statement is more
truthful. The repercussions of the two scenarios are very different, with one leading to the
potential arrest of the male in the scenario. In this scenario and others like it, body fluid
identification is just important as the information obtained from a DNA profile. If both a DNA
profile can be obtained and a body fluid identification can be made, then it could be possible to
link a suspect to the scene of the crime and aid the reconstruction of events, both of which are
important within a forensic investigation.
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1.1.2

Current Methods
Currently, body fluid identification occurs in two steps. First, presumptive tests are

performed to determine whether an unknown stain is more than likely a specific body fluid
(Virkler et al, 2009). While these tests are highly sensitive, they are not highly specific.
Therefore, each presumptive test can react positively with materials other than the targeted body
fluid. That is why a second, confirmatory test is required for a confirmed identification of the
questioned stain. These tests are considered highly specific to human body fluids and are
extremely sensitive (Virkler et al, 2009). Generally, all these methods are destructive to the
questioned stain, which can be problematic when only a small amount of sample is available.
Because each body fluid has its own presumptive and confirmatory tests, there can be a potential
for large amounts of a questioned stain to be consumed if it is suspected to be one of several
body fluids.
In the current body fluid identification system, venous blood, semen, and saliva have
established and reliable tests used for their identification (Virkler et al, 2009). The most common
presumptive test used for the identification of venous blood is the use of the Kastle-Meyer
reagent, used in conjunction with hydrogen peroxide to create a distinct color change (Virkler et
al, 2009). This presumptive test relies on the heme within hemoglobin acting as a catalyst for the
oxidation-reduction reaction between phenolphthalein and hydrogen peroxide. This reaction can
occur in reaction to other chemicals, which is why this is considered a presumptive test. A
common confirmatory test for venous blood is the ABA Hematrace Test, which is a an
immunochromatographic assay, meaning it contains antigens and antibodies. This test is
considered confirmatory because it uses the specific interaction between antigens and antibodies
specific to human hemoglobin to garner a positive result.

3

Similarly, saliva identification relies on a presumptive test with a distinct color change
and an immunochromatographic assay for a confirmatory test. The Phadebas Reagent is the most
commonly used presumptive test for saliva identification. A positive result from this test occurs
when amylase, an enzyme found in saliva, cleaves starch from a dye molecule. This is what
causes the distinct color change (James et al, 2014). Amylase, while found in saliva, is found in
other substances and even other body fluids in smaller amounts. This is why the Phadebas
Reagent can only be used as a presumptive test. Recently, a commercial
immunochromatographic assay, RSID-saliva, was developed for the confirmatory testing of
saliva. It specifically tests for the alpha-amylase found in human saliva, which is considered
specific to humans. It is currently one of the only validated confirmatory tests for saliva (Old et
al, 2009).
Semen identification is slightly different than venous blood and saliva identification. The
most common presumptive testing method is the Acid Phosphatase test. Like the other two
presumptive tests mentioned, a positive result is indicated by a color change. This color change
is due to the reaction between alpha-napththyl phosphate and seminal acid phosphatase. In this
case, Fast Blue B is the color developer (James et al, 2014). Again, like other presumptive tests,
other materials can induce a positive reaction. The most commonly used confirmatory testing
method is microscopy identification of sperm cells with the aid of a staining agent like the
Christmas Tree Stain. Because human sperm cells are dissimilar from other animals in size and
shape, it is a trusted confirmatory method used within the majority of forensic laboratories
(James et al, 2014).
While venous blood, saliva, and semen all have reliable testing methods, other body
fluids including vaginal fluid and menstrual blood do not have reliable testing methods. Several
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Over the last few years, there has been substantial research into the development of new
methods for body fluid identification. In a general sense, there are two types of emerging
identification techniques: molecular techniques and spectroscopic techniques. Molecular
techniques generally focus on unique aspects of genomic material, while spectroscopic
techniques generally focus on the outward characteristics of the body fluid.
Spectroscopic techniques for body fluid identification have become popular recently due
to the many benefits that it provides, including minimal sample preparation and no destruction to
the sample. Within this area, the use of Raman spectroscopy has been gaining momentum for the
identification of body fluids. While researchers have been able to use Raman spectroscopy for
the differentiation of semen, vaginal, fluid, sweat, saliva and blood, there still exists some issues
with this method (Virkler & Lednev, 2008). One of the main issues with this methodology is
that the material that the body fluid is on can interfere with the identification of the body fluid.
While statistical models can be used to correct this, it can be complicated and time-consuming
(McLaughlin et al, 2015). Raman spectroscopy could be a good candidate for the identification
of body fluids, but the method needs more fine-tuning.
Another emerging spectroscopic technique is the use of Attenuated Total Reflectance
Fourier Transformed Infrared (ATR-FTIR) Spectroscopy. The premise behind this technique is
that each body fluid type should absorb infrared light at unique wavelengths (Quinn et al, 2017).
While some researchers have been able to differentiate between the forensically relevant body
fluids using ATR-FTIR, there has been little research on the effect that the substrate background
has on the differentiation of body fluids (Quinn et al, 2017). Because body fluids can be found
on any number of substrates, the unknown effect that it has on ATR-FTIR is a major downfall to
this technique.
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Unlike spectroscopic techniques, molecular techniques do require part of the sample to be
consumed during testing. This amount, however, is generally very small and does not necessarily
require the entire consumption of a sample. Additionally, molecular techniques analyze the
genetic content of body fluids, which can be more complicated that spectroscopic techniques. In
recent years, extensive research has been done on the specificity of messenger RNAs (mRNAs)
to forensically relevant body fluids. Since the conception of this idea, a panel of mRNAs that
have been proven to be specific to forensically relevant body fluids (Nussbaumer et al, 2006).
Despite this, the utilization of mRNAs for body fluid identification is not often used in the field
of forensic science, mainly because mRNAs are prone to degradation. This can be an issue when
body fluids are aged or exposed to unfavorable weather conditions (Zubocov et al, 2010).
Another molecular technique that has been gaining momentum is the use of DNA
methylation sites for body fluid identification. It was proposed that different body fluids could
contain DNA methylation sites specific to each body fluid (Park et al, 2014). There are, however,
issues with this method. Currently, there does not appear to be any studies published that
involved menstrual blood, which is an important body fluid within forensic investigations.
Additionally, the sample preparation can be considered extensive and complicated, which can be
problematic in a laboratory setting.
Another molecular technique for body fluid identification for body fluid identification
that shows immense promise is the use of microRNAs (miRNAs). There has been great success
in the last few years in identifying miRNAs that can be used for body fluid identification. While
many miRNAs have been found to be helpful in the differentiation of body fluids, there has been
little agreement on which miRNAs are the most appropriate for this purpose. It is, however, the
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purpose of this study is to determine which miRNAs throughout literature are the most
appropriate for the identification of forensically relevant body fluids.
1.2

MicroRNAs

1.2.1

Introduction
miRNAs are short, non-coding strands of RNA that are approximately 18-22 base pairs in

length. Up until 1993, miRNAs were thought to have no genetic purpose and were deemed
unimportant. It was at this time, however, that researchers studying nematode genetics
discovered that two small RNA transcripts from the lin-4 were partly responsible for the
regulation of the translation of the lin-14 gene (Lee et al, 1993). These small transcripts were
later termed small RNAs, or microRNAs. It wasn’t until 2000, however, that more miRNAs were
discovered (Bartel, 2014). In the following years, more miRNAs were discovered. These
miRNAs were found to be specific to gene regulations within mammals, fish, worms, flies, and
humans (Bartel, 2004).
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1.2.2

MicroRNA Biogenesis
Since the discovery of miRNAs, much has been discovered about their specificity and

biogenesis. miRNA biogenesis begins in the nucleus of the cell. The biogenesis pathway of a
representative miRNA can be seen in Figure 2.

Figure 2: miRNA Biogenesis Pathway
Adapted from Winter, J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009). Many roads
to maturity: MicroRNA biogenesis pathways and their regulation. Nature Cell Biology, 11(3),
228-234. doi:10.1038/ncb0309-228
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First, miRNAs genes or introns are transcribed within the nucleus by RNA polymerases II and
III. This transcription event results in primary-miRNAs (pri-miRNA), which are precursors to
mature miRNAs (MacFarlane & Murphy, 2010). The pri-miRNAs take a stem-loop structure as
depicted in Figure 2. While still in the nucleus, the pri-miRNAs are cleaved by a protein complex
commonly called the microprocessor that contains the Drosha enzyme and an RNA-binding
protein DGCR8 (MacFarlane & Murphy, 2010). After this cleavage event, the pri-miRNAs are
transformed into pre-miRNAs, which is one step closer to mature miRNA. The pre-miRNAs are
then transported across the membrane and into the cytoplasm. It is at this point that the premiRNAs are cleaved again by an RNase II Dicer enzyme, Dicer-1. This cleavage results in two
miRNA products, the mature miRNA strand and another strand that gets degraded. The mature
miRNA then goes on to serve its function within the cell, while still retaining the stem-loop
structure (MacFarlane & Murphy, 2010).

1.2.3

MicroRNA Analysis
Currently, the gold standard method for analyzing miRNAs is an expression assay using

Real Time Quantitative Polymerase Chain Reaction (RT-qPCR). Generally, analysis is done to
determine whether a miRNA or panel of miRNAs are expressed differently amongst two or more
tissue types. This comparison is done by using the cycle thresholds at which each of the miRNAs
are recognized during the analysis process. Each individual cycle threshold can be correlated to
the original concentration of the miRNA in a specific sample or tissue. By comparing these cycle
thresholds, a comparison can be made on the quantity of miRNAs in each tissue type. One of two
conclusions can be made from the results from the RT-qPCR: either a miRNA is found to only
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be expressed in one tissue or is found to be expressed in a higher or lower abundance compared
to other tissues.
1.2.4

Biomedical Applications of microRNAs
miRNAs have also been extensively researched within humans, especially within cancer

research. Abnormal miRNA expression in human cancer was first described by Calin et al in
2002 (Visone & Croce, 2009). It was found that miR-15 and miR-16 were expressed less in Bcell chronic lymphocytic leukemia cells compared to control cells (Visone & Croce, 2009). The
differential expression of these miRNAs provided a new potential avenue for the diagnosis of Bcell chronic lymphocytic leukemia. Because of the potential seen with miRNAs, this research
study sparked more research of miRNAs in cancer types. As research progressed, miRNAs were
discovered that showed true specificity to certain cancer cell types (Visone & Croce, 2009). True
specificity means that that miRNA was only found in a specific cancer type compared to normal
cells and similar cancer types. Consequently, it was shown that miRNAs can be extremely tissue
specific. At the very least, miRNAs have been shown to be differentially expressed between
body tissues.

1.2.5

Forensic Applications of microRNAs
Through extensive research, miRNAs have been shown to be highly specific. For one, it

has been shown that miRNAs are species specific (Bartel et al, 2010). Additionally, researchers
have been able to extensively show that miRNAs are both tissue specific and even specific to
certain cancers. Because body fluids are a type of body tissue, it is reasonable to assume that it is
possible that miRNAs exist that are specific to forensically relevant body fluids including venous
blood, semen, menstrual blood, vaginal material, and saliva. As mentioned before, miRNAs have
11

been shown to be resistant to degradation. This characteristic of miRNAs suits forensic
investigations because body fluids are exposed to the aging process and poor environmental
environments. If miRNAs can withstand these conditions, they would be beneficial for the
identification of body fluids.
Because miRNAs have been gaining much attention as a potential biomarker for body
fluids, different techniques have been used for the discovery of miRNAs unique to body fluids.
Some of these include microarray assays and capillary electrophoresis. More recently, however,
next generation sequencing has been used by select researchers because it has the ability
sequence the entire miRNA content of body fluids in a short amount of time. The potential data
that could be garnered from this technique may provide many opportunities to discover new
miRNAs that are more specific to body fluids.

1.3
1.3.1

Next Generation Sequencing
Early Development
Next generation sequencing (NGS) has the capacity for the efficient and complete

sequencing of genetic material by sequencing millions, if not billions, of DNA molecules at the
same time (Yang et al, 2014). A full genome can be sequenced by an NGS platform in less than a
day, which took the Human Genome Project 12 years and billions of dollars using the traditional
Sanger sequencing methods (Muzzey et al, 2015). The first iteration of this technology, the 454
Genome Sequencing System, was introduced in 2005. It was considered a high-throughput
sequencing system and was capable of generating 200,000 reads of genomic material 110 base
pairs in lengths (Yang et al, 2014). In 2007, Applied Biosystems introduced a new platform that
relied on an oligonucleotide ligation method and a two-base encoding system. While this
12

platform was able to perform 30 million reads, its base pair length capacity was only 35 base
pairs long (Yang et al, 2014). Over the years, these methods have been refined and the current
methods are capable of performing more reads, with longer read lengths.

1.3.2

Current platforms
NGS technology is a collection of different instruments, each with different sequencing

methods and different uses. Some of these sequencing methods include ion semiconductor
sequencing, single-molecule, sequencing by ligation, and sequencing by synthesis (Muzzey et al,
2015). With ion semiconductor sequencing, the nucleotides are sequenced based on the protons
that are released during processing and the intensity of the resulting signal (Muzzey et al, 2015).
Sequencing by ligation involves using the innate matching abilities of DNA ligase to determine
the sequence of the nucleotides in a DNA sequence (Wehling, 2015). While these two methods
are valid and provide valuable information, it is the sequencing by synthesis technique that
dominates the current field of NGS technology. The main reason this technique dominates the
field is because it is used by the most popular company that provides NGS platforms, Illumina
(Muzzey et al, 2015). Illumina has even released a NGS platform, the MiSeq FGx that is
designed specifically for forensic genomics research.
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Because sequencing by synthesis (SBS) is one of the more popular next generation
sequencing techniques currently used, it is important to understand how it works. Figure 3

Figure 3: SBS Workflow
Adapted from Illumina. (2015). An introduction to next generation
sequencing technology. San Diego, CA: Illumina

depicts the general workflow and biochemistry behind the sequencing by synthesis methodology
used by Illumina. This technique takes advantage of the natural process of DNA replication.
Essentially, DNA replication requires a template DNA strand, free bases to add to the new DNA
strand, and polymerases to link the bases together. SBS utilizes this idea on a much grander scale
and the bases that are being added are fluorescently tagged (Muzzey et al, 2015). Each different
14

base type (Adenine, Tyrosine, Guanine, and Cytosine) has a specific color assigned to it which
allows for their identification during the detection phase of the sequencing. If a certain color is
detected, then that specific base will be identified at a specific position in the genome. There are
several general steps to SBS. Firstly, the RNA samples are prepared for sequencing, which
includes fragmentation and reverse transcription into cDNA. Secondly, hundreds of thousands of
template DNA strands are bound to the surface where the sequencing will take place, also called
a flow cell (Muzzey et al, 2015). Next, these template strands are copied hundreds of times until
a cluster of strands are formed. Once a certain amount of template strands has been formed in
each cluster, the template strands will be replicated at the same time using the fluorescently
labeled nucleotides. At specified times, the replicate pauses and a digital image is formed of all
the strands and the nucleotides are identified based on the color conformation of the digital
images. This stepwise process repeats until all the genetic material is sequenced and reported by
the instrument. The instrument automatically assembles a readable sequence of the genetic
material and statistical manipulation can be done on the information if needed.
It is important to note that each fragment within each sample receives more than one read
from the instrument. Ultimately, a sample could receive anywhere between thousands to millions
of reads. The success of the sequencing depends partly on the number of reads a sample receives.
Generally, the more reads a sample receives, the more successful the sequencing will be.
Additionally, there is a minimum number of reads that each sample needs for successful
sequencing to occur. This minimum number is usually dependent on what is being sequenced.
For example, miRNAs need a minimum of 1-2 million read for successful sequencing. More
reads, however, is preferred.
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1.3.3

Forensic Application
Next Generation Sequencing technology allows for many more avenues for the forensic

science community. For example, it has the potential to be used with forensic laboratories within
casework. In this sense, NGS can be used to garner more information about the genomic content
of body fluids found at the scene. At this stage in its development, it would generally only be
used to assist forensic scientists in determining the identity of an unknown individual.
NGS can also be used within forensic genomic research. For example, it can be used in
research assessing the level of degradation in DNA and how efficient different DNA restoration
techniques are (Gorden et al, 2018). Other potential research uses for NGS include species
identification, identical twin studies, and body fluid identification. Within body fluid
identification, NGS technology can even be used to identify known and discover novel miRNAs
that are unique to individual body fluids.

1.4

Thesis Aims
The overall goal of this research study is to evaluate different miRNAs for their potential

use as specific biomarkers for the identification of body fluids (venous blood, semen, vaginal
fluid, menstrual blood, and saliva). The miRNAs chosen for evaluation will be garnered from
either NGS data or a literature review and then validated using RT-qPCR. For example, if one
miRNA seems to be consistently expressed within venous blood, that miRNA would be chosen
for validation as a potential biomarker for venous blood. If no usable data can be obtained from
the NGS, then a literature search will be performed and a panel of miRNAs will be chosen for
validation. Regardless of which avenue is chosen, validation of the chosen miRNAs will be
achieved through reverse transcription quantitative PCR (RT-qPCR), a gold standard method for
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miRNA validation. Statistical analysis will be performed on this validation and it will be inferred
from there whether any of the evaluated miRNAs are truly specific biomarkers for any of the
body fluids. A miRNA could be considered a specific biomarker for a body fluid if it is
expressed in higher or lower abundance compared to other body fluids that also express the same
miRNA or if it is only expressed in one body fluid. The expression levels need to be statistically
different for differentiation between body fluids to be possible. Thus, this ability to differentiate
between body fluids using a miRNA has the potential to become a universal method for body
fluid identification.
In summary, the four main goals for this thesis research are:
1. Performing Next Generation Sequencing to identify known or discover novel
miRNAs that can be utilized for the identification of five forensically relevant
body fluids including venous blood, menstrual blood, semen, vaginal material,
and saliva.
2. Performing a literature review of existing studies to determine whether there is
any agreement amongst the known miRNAs that have been shown to be potential
biomarkers for the five body fluids being studied.
3. Utilizing real-time quantitative PCR (RT-qPCR) to validate the miRNAs chosen
for evaluation from the information garnered from the next generation sequencing
and the literature review.
4. Performing statistical analysis on the results from the RT-qPCR to determine
whether the miRNAs expression levels are statistically different and will allow for
body fluid differentiation and identification. Therefore, this step will allow us to
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infer whether a universal identification method for body fluids is possible with the
set of miRNAs chosen for evaluation.
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2
2.1

CHAPTER 2: LITERATURE REVIEW
Methods of body fluid collection for research purposes
Throughout literature, there was some disagreement on the collection technique for

forensically relevant body fluids including venous blood, semen, menstrual blood, vaginal fluid,
and saliva. The current study chose the most popular collection technique within the literature.
Within research studies using human venous blood samples, there were generally two
methods used for collection. One of those methods involve blood being collected from the vein
by venipuncture into dry vacutainer tubes that contain some form of EDTA to prevent
coagulation of the blood (Sauer et al., 2014). From there, the blood was either immediately
deposited on a sterile cotton swab or refrigerated until needed. The second method involved
pricking the finger with lancets and immediately depositing it on a sterile cotton swab (Shi et al.,
2017, Sirker et al., 2017). The sample could then be stored at -20˚C until its use. The current
research study utilized the venipuncture method and stored the collected blood at 4˚C.
Afterwards, the whole blood itself was extracted based on the extraction protocol of the
extraction kit used.
Regardless of the research study, the collection of semen was the same throughout. The
male participants were asked to ejaculate into a container, either a conical tube or a specimen cup
(Sauer et al., 2014, Sauer et al., 2016). After the sample was delivered to the appropriate area, the
sample was then either stored at -20˚C or immediately prepared for extraction. The preparation
included either depositing a portion of the sample on a sterile cotton swab or extracting directly
from the semen (Sauer et al., 2014, Sauer et al., 2016).
Within research that utilizes human saliva samples, two collection methods were used.
One included spitting into a container, usually a conical tube, until enough, (1-5 mL), of saliva
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was produced (Sauer et al., 2016, Schweighardt et al., 2015). The other method involved taking
buccal swabs of the inside of the check (Courts & Madea, 2011, Sauer et al., 2014, Sauer et al.,
2016). It is unclear from the literature which technique is superior, but the current study utilized
the spitting method.
Unlike the other body fluids, the collection of vaginal fluid was consistent throughout the
literature. The female participants were asked to collect their own samples by inserting a sterile
cotton swab into the vagina and swabbing the vaginal wall (Sauer et al., 2014, Sauer et al.,
2016). Participants were generally asked to refrain from sexual intercourse for at least 4 days
before sample collection prevent contamination from semen and to collect the samples at least
two weeks after the end of their last menstrual cycle to ensure that there was no contamination of
menstrual blood.
Within research studies using human menstrual blood samples, there were generally two
methods used for sample collection. One method included utilizing used tampons of the female
participants and the other method involved having female participants collecting their own
samples by inserting a sterile cotton swab into the vagina (Sirker et al., 2017, Sauer et al, 2016).
The second method using the sterile cotton swabs was utilized in the current research study to
avoid any contamination from material found in a tampon.

2.2

Early studies for the forensic application of microRNAs
The first mention that miRNAs could be used for body fluid identification was within the

groundbreaking study performed in 2009 by Hanson et al (Hansen et al., 2009). In this study,
Hanson et al was able to show that for each body fluid examined, several different miRNAs were
differentially expressed, thereby allowing the differentiation of several body fluids using
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miRNAs. Due to this development, other researchers have been striving to determine which
miRNAs can be utilized as specific biomarkers for body fluids (Courts & Madea, 2011, Li et al.,
2017, Sauer et al., 2016, Sirker et al., 2017). Despite the research that has been performed in this
area, a consistent panel of miRNAs for body fluid differentiation has yet to be identified.

2.3

Recent studies for the forensic application of microRNAs
Since Hanson’s study in 2009, several research studies have focused on linking miRNAs

to specific body fluids, but there has been a lack of a consistent panel of miRNAs that could be
used for body fluid identification (Courts & Madea, 2011, Li et al., 2017, Sauer et al., 2016,
Sirker et al., 2017). For instance, in 2011, Courts and Madea examined six separate miRNAs
within the context of distinguishing between blood and saliva. Three were chosen to be specific
for saliva and three were chosen to be specific for blood. The researchers were unable to isolate a
miRNA that was exclusive to blood or saliva amongst the chosen miRNAs (Courts & Madea,
2011). Researchers did, however, hypothesize that it could be possible to identify blood or saliva
by using a combination or panel of the miRNAs chosen for each. However, results from this
study can only be applied to saliva and blood. Therefore, whether the chosen miRNAs are
expressed in other relevant body fluids, such as semen or vaginal fluid, has yet to be determined.
The current study looks to investigate five different, forensically relevant, body fluids including
saliva, semen, vaginal fluid, menstrual blood, and venous blood.
Several research studies choose to focus on the identification of only one body fluid
compared to other body fluids. For example, Li et al evaluated several miRNAs for specificity
between menstrual and peripheral blood. The miRNAs were chosen for investigation based on an
extensive literature review of previous research (Li et al., 2017). After validation via RT-qPCR,
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results showed that miR-141-3p was highly expressed in menstrual blood and expressed at much
lower levels in peripheral blood, which allowed for the differentiation between menstrual and
venous blood (Li et al., 2017) After this was discovered, the researchers developed a multi-step
protocol for blood identification. Several miRNAs that were seen to be generalized for blood was
used for the identification of both types of blood. After this, menstrual blood could be identified
by the newly discovered miRNA. While this multi-step process does allow for the identification
of menstrual and peripheral blood, it requires extensive sample preparation and the total testing
time would require several hours. Additionally, more validation on the menstrual blood-specific
miRNA, miR-141-3p, would need to be performed before it could be trusted as menstrual blood
specific.
Another study that focused on the identification of one type of body fluid was performed
by Wang et al in 2015, focused only on saliva (Wang et al., 2015). Eight miRNAs were chosen
for further evaluation due to their apparent specificity to saliva in past research articles and past
microarray studies done by the researchers. The purpose of the study was to determine whether
the miRNAs chosen for validation could be used for the identification of saliva. After validation,
none of the evaluated miRNAs were found to be truly specific to saliva (Wang et al., 2015).
Researchers were, however, able to develop a stepwise strategy using several of the miRNAs to
identify saliva (Wang et al, 2015). While the identification of saliva was eventually possible, the
process that it took to achieve this was highly involved and somewhat complicated. As with the
previously mentioned study involving menstrual blood identification, a multi-step process may
not be conducive to a laboratory testing.
Rather than just focus on the identification of one body fluid at a time, some researchers
attempt to identify as many body fluids as possible by using a panel of miRNAs. Recently, Sirker
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et al. examined 19 miRNAs as potential biomarkers for body fluid identification (Sirker et al.
2017). Of the 19 miRNAs examined, only six showed any level of specificity towards the body
fluids they were thought to be specific for. The researchers found that of those six, miR-451
showed clear differentiation capabilities for peripheral blood and miR-10b showed clear
differentiation capabilities for semen, which enabled identification of both body fluids (Sirker et
al. 2017). Showing clear differentiation between body fluids through the use of miRNA
demonstrates that the aim of the current research to discover miRNAs that can be used to identify
all five body fluids (saliva, semen, vaginal fluid, menstrual blood, and venous blood) has
immense potential. It is important to note however, that the identifications of the body fluids
were based on the differential expression of the miRNAs in multiple body fluids (Sirker et al.
2017). For example, miR-451 was expressed in a higher abundance in peripheral blood as
compared to the other body fluids studied. This trend of differentiation, and not true specificity,
has occurred in the majority of research investigating the link between miRNAs and body fluid
identification. Very few research studies have been able to discover a miRNA that is truly
specific to a body fluid (i.e. isn’t expressed in any other body fluid at all). While identification of
body fluids can be done with differential expression of miRNAs, discovering miRNAs that are
truly specific to an individual body fluid would be the best possible result achievable.
Although miRNAs with true specificity to one body fluid have been difficult to isolate,
one study performed by Sauer et al in 2016 was successful in finding a miRNA that was truly
specific to semen (Sauer et al., 2016). This miRNA, miR-891-5p, was shown to be specific to
semen via RT-qPCR (Sauer et al., 2016). Semen was the only body fluid that showed expression
of miR-891-5p, leading to the conclusion that this miRNA seems to be truly specific to only
semen. This study is very important because it shows that true specificity is possible when trying
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to link a miRNA to a body fluid. It is important to note, however, that further validation should
be done to ensure that miR-891-5p is actually semen specific and is not unique to this study. It is
hopeful, however, that this study did show the potential of miRNAs to be truly specific to
forensically relevant body fluids.

2.4

Next Generation Sequencing for the forensic application of microRNAs
Next Generation Sequencing has seldomly been used very often in relation to identifying

forensically relevant body fluids and even fewer have incorporated miRNAs. One research study,
performed by Giampaoli et al in 2017, investigated the ability of the MiSeq platform (Illumina)
to sequence and identify vaginal secretions among other samples (oral, fecal, and yogurt) and
compared this ability to that of the more traditional method of RT-qPCR analysis (Giampaoli et
al., 2017). Rather than use miRNAs for this purpose, this study simply used extracted DNA from
the samples in question. Results showed that the RT-qPCR method is usually sufficient for
vaginal fluid identification. The MiSeq system, however, was shown to be effective in
determining if a sample was vaginal material when RT-qPCR analysis was inconclusive
(Giampaoli et al., 2017). Because this NGS system showed some success with vaginal fluid
identification, more research could be done with other forensically important body fluids.
Because Next Generation Sequencing platforms have the ability to sequence RNA and even
miRNAs, there is the potential that it can be used to identify miRNAs that could be used for
body fluid identification.
One study did, in fact, use Next Generation Sequencing technology to identify a panel of
miRNAs that appeared to be specific to forensically relevant body fluids. In 2016, SeasholsWilliams et al used the HiSeq platform supplied by Illumina® to sequence the small RNAs
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found in venous blood, semen, vaginal fluid, menstrual blood, saliva, urine, feces, and
perspiration (Seashols-Williams et al, 2016). Results from the NGS analysis showed several
miRNAs that appeared to be specific to individual body fluids based on their expression. The
panel of miRNAs developed from the NGS data was validated using RT-qPCR, which is the
standard method. It was found that none of the miRNAs identified as potentially specific to body
fluids by the HiSeq platform actually showed true discriminatory capabilities for the body fluids
investigated (Seashols-Williams, 2016). The identification of the body fluids could only
performed by the traditional differential expression analysis. Therefore, there seems to be a
distinct lack of predictive capabilities of the HiSeq platform to discover miRNAs that are body
fluid specific. However, there were distinct limitations with this study, including the fact that the
cohort of donors were of a similar demographic and small sample sizes were used for the
sequencing step, which could have limited the extent of miRNAs that were sequenced. With a
larger sample size and a more diverse cohort of donors, there is the potential that NGS could
successfully predict miRNAs that are specific to body fluids.
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3.1

CHAPTER 3: MATERIALS AND METHODS
Scope of Research
This research study investigated the use of miRNAs as a biomarker for identifying

forensically relevant body fluids including venous blood, semen, saliva, menstrual blood, and
vaginal fluid. Real time quantitative polymerase chain reaction (RT-qPCR) was used to validate
the miRNAs chosen from an extensive literature review.

3.2

Body Fluid Collection
Following University of New Haven Institutional Review Board (IRB) approval, venous

blood (n=9), semen (n=7), saliva (n=10), menstrual blood (n=10), and vaginal fluid (n=10) was
collected from volunteers with informed written consent. Each participant was assigned a
random code for each of their donated samples. Any individualizing information connected to a
participant remained only in the hands of the co-principal investigator, Dr. Claire Glynn.
For semen, salvia, menstrual blood, and vaginal fluid donation, participants were
permitted to take home a collection kit and collect their sample personally. Once the samples
were collected, participants were asked to return the samples to the designated freezer in room
415 on the fourth floor of Dodd’s Hall for storage at -20˚C until further use. For venous blood
donation, sample collection was performed by medical personnel at the University of New
Haven’s Health Services clinic via venipuncture. Samples were returned to the designated
refrigerator in room 415 on the fourth floor of Dodd’s Hall at the University of New Haven for
storage at 4˚C until further use.
For semen donation, participants were asked to ejaculateonce into a sterile 50 mL Falcon
Polypropylene Conical Tube after proper hygiene practices were performed.
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For saliva donations, participants were asked to collect fluid saliva by spitting into a 15
mL Falcon Polypropylene Conical Tube to at least the 2.0 mL mark. Participants were also asked
to refrain from eating or drinking anything for at least thirty minutes prior to both collections.
For menstrual blood donation, participants were asked to collect the samples on the
heaviest day of the menstrual cycle, which was done to ensure that there was ample menstrual
blood to collect from. Participants were given three sterile swabs to swab the internal vaginal
wall, making sure to swab a different area each time.
For vaginal fluid donation, participants were asked to abstain from sexual intercourse for
at least four days prior to sample collection to prevent contamination from semen in the vaginal
cavity. Additionally, participants were asked to wait until at least two weeks after the end of their
menstrual cycle to collect the samples to ensure that there was no contamination from menstrual
blood. Sample collection was carried out using the same protocol as menstrual blood collection.
For the sample collections that were performed by the participants themselves, the
participants were asked to ensure that the samples were kept as cold as possible up until they
were placed in the -20 ˚C freezer in Dodds Hall. This will ensure that the sample will be in its
best condition before extraction.
3.3
3.3.1

Methods
RNA Extraction Procedure: miRNeasy Mini Kit
Before extraction occurred, donated samples were taken out of storage and allowed to

thaw to room temperature. Liquid fluids (venous blood, semen, and saliva) were extracted using
500 mL of the fluid. Vaginal material and menstrual blood were collected using sterile swabs and
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extraction, therefore, was performed directly on those swabs. The swab head was removed from
the swab using sterile techniques and the extraction was performed on the swab head. Figure 4

Figure 4: miRNeasy Mini Procedure
Adapted from Qiagen (2012). RNeasy® Mini Handbook. Qiagen.
Hilden, Germany
depicts the general procedure for RNA isolation using the miRNeasy Mini Kit (Qiagen®).
Using this kit, RNA isolation was performed via a combination of a guanidine-isothiocyanate
lysis step and a silica-membrane purification step. Following cell lysis and disruption, ethanol
was added to the samples to enhance binding interactions between the RNA and silica
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quantification assays using fluorescent probes. It is considered to be more comprehensive and
reliable than UV-Vis methods. Additionally, it is considered more human specific. Refer to
Appendix B for more detailed instructions on the proper protocol.

3.3.2.3 Agilent Bioanalyzer
Lastly, the Agilent 2100 Bioanalyzer was utilized using both the Small RNA kit and the
RNA 6000 Nano kit. The chips utilized within these kits essentially perform small-scale capillary
electrophoresis. The Small RNA kit was utilized to determine the percentage of miRNA within
each sample, compared to the other small RNA content. The Nano 6000 kit served two purposes:
the first purpose was to determine the human specific concentration of RNA within each extract
and the second purpose was to provide a quality assessment of the of the sample in the form of
an RNA integrity number (RIN). Refer to Appendix C and D for more detailed instructions on
the proper protocol for each kit.

3.3.3

Next Generation Sequencing via MiSeq FGx Platform

3.3.3.1 Sample Preparation Using TruSeq Small RNA Protocol
After quantification of the samples was complete, several rounds of sequencing were
performed using venous blood, semen, vaginal fluid, menstrual blood, and saliva.
The TruSeq Small Library Prep Reference Guide was followed for sample preparation.
On Day 1 of sample preparation, 3’ and 5’ ends of the miRNA strands within the sample were
ligated with RNA 3’ Adapter and RNA 5’ Adapter, respectively. This was done by pipetting and
mixing specific volumes of the samples and Illumina® provided consumables together and
subjecting the samples to specific temperatures at pre-determined periods of time. Then, the
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samples were reverse transcribed into complementary DNA (cDNA) using SuperScript II
Reverse Transcriptase provided by Thermo Fisher Scientific®. A thermal cycler was used for
incubating the samples at 50˚C for one hour. After reverse transcription was completed, the
individual samples were indexed with a specific RNA PCR Primer Index. Each sample received
a different index, which allowed the samples to be easily identified. Amplification was then
performed on a thermal cycler for 15 cycles, which was the maximum number of cycles
recommended (see Appendix E for full details). At this point the samples were stored at -20˚C
until further used.
On Day 2 of the sample preparation, the cDNA samples were pooled into one
microcentrifuge tube, mixed together and purified via gel electrophoresis. A 1X Novex TBE
Buffer, the XCell SureLock System (as depicted in Figure 5), Novex TBE gels (6%, 10 wells,

Figure 5: XCell SureLock System Set Up
As adapted from fishersci.com
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The bands were placed in a 0.5 mL gel breaker tube nested in a 2.0 mL microcentrifuge
tube and spun down. Ultrapure water (300 µL) was added to the gel debris within the 2.0 mL
microcentrifuge tube and shaken at room temperature for four hours. The final sample was
concentrated using a series of washes with glycogen, 3M NaOAc, and ethanol (for a full
protocol, please see Appendix). The resulting pellet was resuspended in 10 uL of 10 mM TrisHCl, pH 8.5. The quality and quantity of the purified DNA was analyzed using the DNA 1000
kit in conjunction with the 2100 Bioanalyzer provided by Agilent Technologies®. The sample
was then stored at -20˚C until further use. Please refer to Appendices E-G for full protocols.

3.3.3.2

Sequencing of Prepared Samples with MiSeqFGx
Before sample preparation started, the MiSeqFGx was prepared for sequencing. A sample

sheet was created detailing the necessary information for each sample including what index
paired with each sample.
The final sample, or Library, was diluted to a 4 nM concentration based on the
concentration obtained from the 2100 Bioanalyzer. Then, the 4 nM library was denatured and
brought to a concentration of 12 pM.
The PhiX control was then diluted down to a concentration of 4 nM. The diluted PhiX
control was then denatured and diluted down to a concentration of 12 pM. The 12 pM library
was then spiked with a 25% volume of the 12 pM PhiX control.
The KV 3 reagent cartridge was thawed and then prepared for sequencing. Then, 600 µL
of the final library (spiked with 25% 12 pM PhiX) was loaded into the cartridge. Then the
cartridge was inserted into the MiSeqFGx and a sequencing run was started. After the run

35

completed, a post-run wash was performed. Refer to Appendixes E-G for more detailed
instructions on the proper protocols for Next Generation Sequencing sample preparation.

3.3.3.3

Data Analysis
The data files from the MiSeq FGx were taken from the instrument and uploaded to an

Illumina sponsored website called BaseSpace, which analyzed the raw sequencing data. This is
also the website where statistical analysis could be done on said data.

3.3.4

Literature Review for Unique miRNAs
A literature search was performed to determine which miRNAs have been shown to be

specific to the five body fluids being studied (menstrual blood, semen, vaginal material,
menstrual blood, and saliva). A panel of miRNAs was chosen based on the literature review for
further validation.

3.3.5

RT-qPCR Validation of miRNAs

3.3.5.1 Reverse Transcription
Reverse transcription (RT) was performed to transform the extracted miRNA into its
complementary DNA (cDNA). For each sample, the reaction was performed using the following
amounts of reagents represented in Table 1.
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Table 1: Reagent Volumes for Reverse Transcription
Reagent

Volume Added to Master Mix per sample

Nuclease Free water

4.57 µL

dNTP mix (100nM)

0.17 µL

10x RT Buffer

1.65 µL

miRNA Specific Stem Loop Primer (50nM)

3.1 µL

Multiscribe (50 U/µL)

1.1 µL

RNase Inhibitor (20 U/µL)

0.21 µL

Premix Volume

10.0 µL

Total/miRNA (1-10 ng)

5.0 µL

Total Reaction Volume

15.0 µL

Reverse transcription was performed in a hood with functioning laminar flow. The hood and
items within the hood were cleaned with 70% Industrial Reagent Alcohol and underwent fifteen
minutes of UV exposure before its use. This was done to maintain a sterile environment. The
components of the Master Mix were allowed to thaw on ice before use. The Master Mix was
prepared in brown 1.5 mL microcentrifuge tubes to protect the miRNA-specific Stem Loop
Primers from the light. A Master Mix was prepared for each individual miRNA for the samples
chosen for analysis.
miR-16 was chosen as an endogenous control for all five body fluids and, therefore, was
reverse transcribed for every single sample chosen for analysis.
Each prepared sample was centrifuged prior to being loaded onto the thermal cycler. The
reverse transcription reaction was performed using a GeneAMP® PCR System 9700 Thermal
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Cycler (Applied Biosystems). For each miRNA target group, a negative RT blank control was
prepared. These blanks consisted of the RT master mix and biology grade water. This was
included to ensure no contamination occurred during the reverse transcription step. Table 2
depicts the parameters that the Thermal Cycler was run at.
Table 2: Thermal Cycler Parameters for RT Reaction

Time

Temperature

Hold

30 Minutes

16˚C

Hold

30 Minutes

42˚C

Hold

5 Minutes

85˚C

Hold

∞

4˚C

After the RT reactions were completed, the cDNA samples were centrifuged and the
placed into storage at -20˚C until further use.

3.3.5.2 Relative Quantification – Polymerase Chain Reaction (qPCR)
After proper thawing on ice, the cDNA samples were amplified using the ABI 7500 Real
Time PCR System (Applied Biosystems). Relative quantification PCR involves the real time
monitoring of the progress of the amplification. The quantities of the target molecules are
measured after each cycle completes. Each cycle consists of a denaturing step, a primer
annealing step, and a template extension step. The process as a whole consists of three separate
phases. The first phase is the exponential phase, where the amount of product is doubled during
each cycle. The next two phases, the linear phase and plateau phase, have a reduced detection
limit and, therefore, are less important for the calculation of relative quantification. In the current
38

procedure, the PCR reaction ran for 40 cycles. If the target miRNA was in a particular sample, it
would be expected that the amplified products within the sample would reach the Cycle
Threshold (Ct) by the end of the 40 cycles. The Cycle Threshold is the point at which the
amplified product produces a detectable fluorescent signal. For example, a lower amount of
starting material will take longer to accumulate to a detectable level and will, therefore, result in
a higher Ct-value. The Ctvalue can then be used to make conclusions on the relative quantities of
the target within each sample.
All reactions were prepared in a vented hood that was cleaned with 70% Industrial Reagent
Alcohol and treated with UV light for 15 minutes before use. Throughout the preparation
process, a clean and sterile environment was maintained. The cDNA samples that had been
previously prepared were allowed to thaw on ice. A master mix for each miRNA target were
prepared in 1.5 mL brown centrifuge tubes to protect the light sensitive miRNA target reagents.
Each sample was prepared in triplicate using a master mix containing the reagents in Table 3.
Table 3: Master Mix for Real Time PCR
Reagents

Master Mix Volume (per one sample)

Taqman® Universal PCR Master Mix

5.0 µL

Nuclease Free Water

3.8 µL

miRNA PDAR

0.5 µL

Total Master Mix Volume (Premix)

9.3 µL

cDNA

0.7 µL

Total Volume of Reaction

10.0 µL
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The master mix and samples were dispensed in a 96-well plate. Along with the samples, a
no target control (NTC) was included within the plate. The NTC consisted of the PCR Master
mix and nuclease free water, with no cDNA present. This was included to determine if any
contamination occurred during this step. The Reverse Transcription blank (RT) for each miRNA
target was also included with each of the reactions. In each of these instances, contamination
would be seen as amplified cDNA product. Additionally, each plate included an inter assay
control (IAC) to ensure that each separate plate was performing in a similar manner. The IAC
was determined to be the sample with the highest original RNA concentration and was reverse
transcribed using the miRNA-16 target. Figure 7 depicts an example of a potential set-up of a

Figure 7: Example of a 96-well Plate Set Up
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96-well plate that holds eight samples of two different miRNA targets (a and b), the appropriate
NTC, the appropriate, RT blanks, and the IAC.
After all of the components of a plate reaction were prepared, the plate was centrifuged
for approximately 30-60 seconds. It was then loaded into the ABI 7500 Real-Time PCR system
and run at the following setting with a final reaction volume of 10 µL (Table 4).
Table 4: The Running Parameters of the ABI 7500 Real-Time PCR System
Time

Temperature

Hold

2 Minutes

50˚C

Hold

10 Minutes

95˚C

15 Seconds

95˚C

60 Seconds

60˚C

40 Cycles

After the run was complete, the plate and its components were disposed of in biohazardous
waste.

3.3.6

RT-qPCR Data Statistical Analysis

miRNA expression analysis requires the use of an endogenous control. In this thesis, an
endogenous control is a miRNA that has expression levels that are known to be relatively stable
throughout the body fluids being tested. Based on a literature review, miR-16 was chosen as the
endogenous control. Therefore, each miRNA target in each sample being studied was expressed
relative to the miR-16 expression in order to normalize the results. An average Ct value was
calculated based on the triplicate of each sample. The average Ct value for the endogenous
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control for that sample was subtracted from the target miRNA of interest. This value was
considered the ΔCt value, as seen in Equation 2.
!"# = "%('()*+' -./01) − "%(+456*+4678 964')6:)
Equation 2: ΔCt Value
Statistical analysis was carried out using the ΔCt-values of each sample using the
statistical software package, Minitab 18.0 (Mintab Ltd). Two sample T-tests and one-way
ANOVA was used to determine association and comparison between different target miRNA
groups and determine the possible statistical significance. Results with a p-value less than 0.05
were considered statistically significant.

42

CHAPTER 4: RESULTS

43

4

CHAPTER 4: RESULTS

4.1
4.1.1

RNA Quantification Results
Venous Blood
All venous blood samples had measurable RNA content with each method used. The

average concentrations for the total RNA content using NanoDrop OneC method, Qubit method,
and the RNA 6000 Nano kit/2100 Bioanalyzer method were 20.02 ng/µL, 27.934 ng/µL, and
9.67 ng/µL respectfully. The average RNA Integrity number (RIN) was 4.7. It is important to
note that with both the Qubit method and RNA 6000 Nano kit/2100 Bioanalyzer, several samples
were too low in concentration for the instrument to determine the concentration or the RIN.
According to the Small RNA/2100 Bioanalyzer method, the average concentration for small
RNA within the sample was 17.78 ng/µL and the average miRNA concentration was 4.76 ng/µL.
A full representation of the data from each of these methods can be found in the Appendix.

4.1.2

Menstrual Blood
All menstrual blood samples had measurable RNA content with each method used. The

average concentrations for the total RNA content using NanoDrop OneC method, Qubit method,
and the RNA 6000 Nano kit/2100 Bioanalyzer method were 120.20 ng/µL, 150.06 ng/µL, and
99.23 ng/µL respectfully. The average RNA Integrity number (RIN) was 4.4. It is important to
note that with the Qubit, several samples were too low in concentration for the instrument to
determine the concentration or the RIN. According to the Small RNA/2100 Bioanalyzer method,
the average concentration for small RNA within the sample was 362.23 ng/µL and the average
miRNA concentration was 98.44 ng/µL. A full representation of the data from each of these
methods can be found in the Appendix.
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4.1.3

Semen
All semen samples had measurable RNA content with each method used. The average

concentrations for the total RNA content using NanoDrop OneC method, Qubit method, and the
RNA 6000 Nano kit/2100 Bioanalyzer method were 54.16 ng/µL, 47.91 ng/µL, and 27.38 ng/µL
respectfully. The average RNA Integrity number (RIN) was 2.93. It is important to note that with
both the Qubit method and RNA 6000 Nano kit/2100 Bioanalyzer, several samples were too low
in concentration for the instrument to determine the concentration or the RIN. According to the
Small RNA/2100 Bioanalyzer method, the average concentration for small RNA within the
sample was 189.51 ng/µL and the average miRNA concentration was 90.023 ng/µL. A full
representation of the data from each of these methods can be found in the Appendix.

4.1.4

Vaginal Material
All vaginal materials samples had measurable RNA content with each method used. The

average concentrations for the total RNA content using NanoDrop OneC method, Qubit method,
and the RNA 6000 Nano kit/2100 Bioanalyzer method were 372.26 ng/µL, 413.84 ng/µL, and
314.77 ng/µL respectfully. The average RNA Integrity number (RIN) was 3.88. According to the
Small RNA/2100 Bioanalyzer method, the average concentration for small RNA within the
sample was 1241.65 ng/µL and the average miRNA concentration was 162.77 ng/µL. A full
representation of the data from each of these methods can be found in the Appendix.
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4.1.5

Saliva
All saliva samples had measurable RNA content with each method used. The average

concentrations for the total RNA content using NanoDrop OneC method, Qubit method, and the
RNA 6000 Nano kit/2100 Bioanalyzer method were 76.92 ng/µL, 112.87 ng/µL, and 86.82
ng/µL respectfully. The average RNA Integrity number (RIN) was 2.64. It is important to note
that with both the Qubit method and RNA 6000 Nano kit/2100 Bioanalyzer, several samples
were too low in concentration for the instrument to determine the concentration or the RIN.
According to the Small RNA/2100 Bioanalyzer method, the average concentration for small
RNA within the sample was 23.22 ng/µL and the average miRNA concentration was 11.23
ng/µL. A full representation of the data from each of these methods can be found in the
Appendix.

4.2

Sequencing Results
The first several attempts at sequencing various samples, the sequencing run failed without

collecting any data. After consulting with Illumina representatives and an on-site visit from an
Illumina engineer, it was determined that the MiSeq FGx sequencing platform had been
improperly aligned and would not have produced any successful results.
After the instrument was properly calibrated, another sample run was attempted. While the
run completed without errors, no miRNAs were identified as being sequenced. Other small
RNAs, however, were successfully sequenced. Through consultations with Illumina
representatives, one last sequencing attempt was performed with two body fluid samples that had
the highest RIN to determine if sequencing would be successful in this case. The reasoning for
this was that if the sequencing was not successful with only two sample of high quality, then
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there was little chance that it would be successful with more samples of lower quality. The
sequencing run completed without errors, but no miRNAs were successfully sequenced. Like
previous runs, other small RNAs were sequenced. Figure 8 shows a representative pie chart

Figure 8: Sequencing Results

showing the final sequencing results from these runs. After the last, unsuccessful sequencing
results, miRNAs were chosen for further validation based on an extensive literature review.

4.3

miRNAs Chosen from Extensive Literature Review
After an extensive literature review, several miRNAs were chosen for further validation

based on their previously reported specificity for specific body fluids. Additionally, a miRNA
was chosen for normalization purposes. Table 5 shows the miRNAs chosen for validation and for
which body fluid they were reported to be specific for.

47

Table 5: miRNAs Chosen for Further Validation
miRNA Chosen for Validation

Body Fluid Biomarker

miR-451

Venous Blood

miR-412

Menstrual Blood

miR-891a

Semen

miR-10b

Semen

miR-205

Saliva

miR-124a

Vaginal Fluid

miR-16

Normalizer

The miRNAs were chosen for further validation because they were the most commonly
associated miRNAs to the particular body fluid they were chosen for. While they were not the
only miRNAs found in the literature search, they appeared the most and seemed to be the most
specific to the chosen body fluids.

4.4
4.4.1

miRNA Expression via RT-qPCR Results
Statistical Parameters
For each miRNA, the difference in the expression levels across all five body fluids was

assessed with a one-way ANOVA test. The p-value required for a statistically significant
difference in expression was less than 0.05. For each miRNA, the expression level of the target
body fluid was compared to the other four body fluids to determine if the difference was
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statistically significant. The p-value required for a statistically significant difference in
expression was less than 0.05.

4.4.2

miR-451 Expression Results
Figure 9 shows the results of the statistical analysis of the expression of miR-451

represented in the form of boxplots.

Figure 9: miR-451 Expression Boxplots
An ANOVA test performed in Minitab 18 showed that there was a statistically significant
difference in the expression of miR-451 across all five body fluids after normalization. As the
statistical results for miR-451 expression shows, when comparing venous blood to saliva, the pvalue was 0.139, which was above the p-value required for a statistically significant difference.
When comparing venous blood to menstrual blood, the p-value was 0.058, which was also above
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the required p-value for a statistically significant difference. When comparing venous blood to
semen and vaginal fluid, however, the p-values < 0.05, indicating that these differences in
expression levels were statistically significant. It is important to note that the range of expression
levels for both saliva and semen does appear be large.

4.4.3

miR-412 Expression Results
Figure 10 shows the results of the statistical analysis of the expression of miR-412

represented in the form of boxplots.

Figure 10: miR- 412 Expression Boxplots
An ANOVA test performed in Minitab 18 showed that there was a statistically significant
difference in the expression of miR-412 across all five body fluids after normalization. As the
results show, the p-value was 0.072 was when comparing the expression levels of miR-412
between menstrual blood and venous blood. Because this p-value was above the p-value required
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for a statistically significant difference in expression levels, this difference cannot be considered
significant. When comparing menstrual blood to vaginal fluid, the expression levels appeared to
overlap. When statistical testing was performed, however, the p-value was 0.022, which was
below the required p-value for a statistically significant difference in expression levels. This
indicated that the difference in expression levels between these two body fluids was statistically
significant. When comparing menstrual blood to saliva and semen, the p-values < 0.05,
indicating that these differences in expression levels were statistically significant. It is important
to note that the range of expression levels for saliva does appear to be large.

4.4.4

miR-891a Expression Results
Figure 11 shows the results of the statistical analysis of the expression of miR-891a

represented in the form of boxplots.

Figure 11: miR-891a Expression Boxplots
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An ANOVA test performed in Minitab 18 showed that there was a statistically significant
difference in the expression of miR-412 across all five body fluids after normalization. As the
results for miR-891a expression shows, the expression levels for semen and saliva appear to
overlap. The statistical testing, however, showed that the p-value was 0.026, which was lower
than the p-value required for a statistically significant difference between the expression levels.
Therefore, semen and saliva showed a statistically significance difference in their expression.
When comparing semen to venous blood, menstrual blood, and vaginal fluid, the p-values were
also less than the p-value required for statistically significant difference in expression levels.
This indicated that the difference between these body fluids was statistically significant.
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4.4.5

miR-10b Expression Results
Figure 12 shows the results of the statistical analysis of the expression of miR-891a

represented in the form of boxplots.

Figure 12: miR-10b Expression Boxplots
An ANOVA test performed in Minitab 18 showed that there was a statistically significant
difference in the expression of miR-10b across all five body fluids after normalization. As the
results for miR10b expression shows, the p-value attributed to the difference between semen and
vaginal fluid was 0.124. Because this p-value exceeds 0.05, this difference was not statistically
significant. The results also show that the differences in expression levels between semen and
venous blood, saliva, and menstrual blood have p-values less than 0.05. This indicates that these
expression differences are statistically significant. The results also show that the expression
differences between venous blood and all other body fluids is also statistically significant.
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4.4.6

miR-205 Expression Results
Figure 12 shows the results of the statistical analysis of the expression of miR-891a

represented in the form of boxplots.

Figure 13: miR-205 Expression Boxplots
An ANOVA test performed in Minitab 18 showed that there was a statistically significant
difference in the expression of miR-10b across all five body fluids after normalization. When
comparing the expression levels of saliva to semen and vaginal fluid, the p-values were both
greater than 0.05 (0.066 and 0.156, respectively). This indicated that the difference between the
expression levels was not statistically significant. The expression results also shows that when
comparing saliva expression levels to the expression levels of menstrual blood, the p-value was
0.020, which indicated that the difference between the expression levels was statistically
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significant. Additionally, venous blood was shown to have no miR-205 expression. It is
important to note that the range of expression levels for saliva was extensive.
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CHAPTER 5: CONCLUSIONS

5.1

Sequencing via MiSeq FGx Platform
After several attempts of sequencing the miRNA content within the body fluid samples

using the MiSeq FGx Platform in conjunction with the TruSeq Small RNA Kit, there was no
usable miRNA data. Because other types of small RNA were successfully sequenced within the
samples, the sequencer is capable of sequencing RNA content. Based on these results, it appears
that utilizing the MiSeq FGx platform with the TruSeq Small RNA kit may not be the optimal
technique for sequencing the miRNA content in body fluid samples.

5.2
5.2.1

miRNA Expression via RT-qPCR
miR-451 Expression Results
According to studies performed by Hansen et al, Courts et al, Sirker et al, and Mayes et

al mir-451 has showed greater expression levels in venous blood as compared to other
forensically relevant body fluids. It was the goal of this study to determine if miR-451 could be
used to not only differentiate between blood and other body fluids, but also differentiate between
venous blood and menstrual blood. Based on the statistical analysis of miR-451 the current
study, showed that miR-451 couldn’t be used to differentiate venous blood from menstrual blood
and saliva because the differences between the expression levels was not statistically significant.
Venous blood, however, could be differentiated from both semen and vaginal fluid using miR451 because the differences in the expression levels was statistically significant. More
specifically, venous blood was more highly expressed compared to that of semen and vaginal
fluid.
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These results are inconsistent with the studies found in the literature. The majority of the
studies found that miR-451 could, at the very least, be used to differentiate between blood and all
other body fluids. The fact that in this study venous blood could not be used to differentiate
between venous blood and saliva contradicts these findings.
The range of expression levels of miR-451 within semen and saliva is quite large. This
can be problematic because it shows great variability of expression within one body fluid. This
may make it more difficult to make body fluid identification using miR-451. Ideally, the
expression levels of a miRNA should be small so the results can be trusted more. A larger
sample size may minimize this effect.
5.2.2

miR-412 Expression Results
It was previously reported by Hansen et al and Mayes et al, that miR-412 showed

increased expression in menstrual blood compared to other forensically relevant body fluids,
including menstrual blood. This differential expression allowed researchers to identify menstrual
blood compared to other body fluids. It was the goal of this study to determine if miR-412 could
be used to differentiate between menstrual blood and other body fluids, especially venous blood.
Based on the statistical analysis of the expression levels of miR-412 within this study, it cannot
be used to differentiate between menstrual blood and venous blood because the difference
between the expression levels was not statistically significant. These results are inconsistent with
that found within the published literature, which indicated miR-412 expression should
significantly different between menstrual and venous blood.
The results from this study do, however, show that miR-412 can be used to differentiate
menstrual blood from semen, saliva, and vaginal fluid because the difference between the
expression levels was statistically significant. More specifically, the expression levels of miR58

412 are more highly expressed in menstrual blood compared to semen, saliva, and vaginal fluid.
This increased expression is compatible with what is seen in the published literature. Overall,
based on the results of this study, miR-412 can be used to differentiate between blood (venous
and menstrual) and other forensically relevant body fluids.
It is important to note that the range of expression levels of miR-412 in saliva was large.
As stated before, this can be problematic because this shows great variability of expression of
miR-412 within saliva, which could make it more difficult to successfully differentiate saliva
from menstrual blood using this miRNA.
5.2.3

miR-891a Expression Results
It was previously reported by Sauer et al, Mayes et al, Seashols-Williams et al, and Tian

et al, that miR-891a was more abundantly expressed within semen compared to other body
fluids. This differential expression lead to the ability of researchers to identify semen using miR891a. It was the goal of this study to validate the identification capabilities of miR-891a based on
differential expression. Based on the statistical analysis of the expression of miR-891a across the
body fluids, miR-891a can be used to differentiate semen from all other body fluids because the
difference between the expression levels was statistically significant. More specifically, semen
was more highly expressed compared to all other body fluids. These results are consistent with
that found in the literature, with the exception of Saur et al which showed that miR-891a was
only expressed in semen (Saur et al, 2016). This would indicate that miR-891a is not truly
specific to semen as indicated in Saur et al.
The range of expression levels of miR-891a in saliva, however, is large. Although
difference the expression levels between semen and saliva is statistically significant, the high
variation of miR-891a expression in saliva could potentially encroach into the expression levels
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of semen. This could make a body fluid identification slightly more difficult. However, more
experiments should be done to determine if this could truly become an issue.

5.2.4

miR-10b Expression Results
According to previous studies performed by Hanson et al, Sauer et al, Sirker et al, Mayes

et al, and Tian et al, the expression of miR-10b was shown to be more abundant in semen
compared to other forensically relevant body fluids. The differentiation and identification
capabilities of miR-10b was the basis of why it was chosen for further validation in this study. It
was the goal of this study to determine if miR-10b could be used to differentiate between semen
and other body fluids. Based on the statistical analysis of miR-10b, the p-value attributed to the
difference in expression between semen and vaginal fluid was 0.124. Because this value was
greater than 0.05, this difference was not statistically significant. Therefore, miR-10b could not
be used to differentiate between semen and vaginal fluid, which contradicts previously reported
findings.
The results also show that miR-10b can be used to differentiate semen from venous
blood, saliva, and menstrual blood because the expression level differences were statistically
significant. These findings do comply with previously reported findings.

5.2.5

miR-205 Expression Results
miR-2015 was chosen for validation because a previous studies performed by Hanson et

al, Wang et al, Mayes et al, and Van der Meer et al showed that it appeared to be differentially
expressed in saliva compared to other forensically relevant body fluids. It was the goal of this
study to determine if miR-205 could be used to differentiate between saliva and other body
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fluids. Based on the statistical analysis of the expression levels of miR-205 within this study, the
identification capabilities of miR-205 were not particularly strong. The expression levels show
that miR-205 could not be used to differentiate saliva from semen or vaginal fluid because the
differences in the expression levels were not statistically significant. This lack of differentiation
abilities of miR-205 directly contradicts previously published results.
The expression levels of miR-205, however, did show that it could be used to
differentiate between saliva and menstrual blood because the difference between the two
expression levels was statistically significant. This does agree with the previously published
results mentioned above. The expression levels of miR-205 also shows that miR-205 was not
expressed in venous blood. This lack of expression in venous blood was also seen in Wang et al
and Mayes et al). Technically, these results do indicate that miR-205 can be used to differentiate
between venous blood and saliva based on the lack of expression in venous blood. Overall, the
ability to utilize miR-205 to differentiate between saliva and menstrual/venous blood is
consistent with the literature search.
Like with the other miRNAs, the range of expression levels of miR-205 in saliva was
large. In this case, this causes an issue being able to differentiate between saliva and the other
body fluids because the large expression levels of saliva overlap that of semen and vaginal fluid.
Therefore, the identification of salvia becomes more difficult because of this large expression
range. The large expression range may be due the small sample size and increasing the sample
size may correct this issue slightly.

61

CHAPTER 6: DISCUSSION

62

6
6.1

CHAPTER 6: DISCUSION
Next Generation Sequencing
There may be several reasons for this sequencing failure. An initial concern for the failure

of the sequencing was errors during sample preparation. However, because Illumina
representatives were present several times during sample preparation and did not point out any
mistakes, this seems like an unlikely option. Another potential point of error was that the quality
of the RNA samples being sequenced was not optimal for sequencing. Because the last
sequencing run consisted of the two samples of the best quality and the sequencing still failed,
this also seems to be unlikely. A more likely reason for the sequencing failure is that the MiSeq
FGx may not have extensive enough sequencing capabilities to sequence the miRNAs within the
samples. In other words, the MiSeq FGx may not produce enough sequencing reads per sample
for the analytical software within the instrument to sequence the miRNA content in the sample.
This seems like the most likely scenario as no body fluid sample reached the required amount of
reads for successful sequencing, which was 1-2 million reads. Without more experimentation,
however, there is no way to determine the true reason or combination of reasons why the miRNA
content in the samples were not able to be sequenced.

6.2

miRNA Expression Analysis
The results from this study show both agreement and disagreement with previously

published studies evaluating miRNAs for body fluid identification. This illustrates the need for
more extensive research to determine an appropriate panel of miRNAs for body fluid
identification. Ideally, the expression levels of the miRNAs within the panel ultimately chosen
for body fluid identification needs to be reliably reproduced by several different people working
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independently of one another. Additionally, there should be little to no overlap in expression of
each miRNA in the different body fluids. This ensures that proper identification can be
performed for each body fluid. Because this was not achieved within in this research study or
any other ones, there needs to be more research done.

6.3

Future Works
The range of expression of saliva within each miRNA was quite extensive. This made it

more difficult for saliva to be distinguished from other body fluids. The reason for this large
expression range for saliva is unknown. It is possible that this could be mediated by increasing
the number of saliva samples used within RT-qPCR. A larger sample size may be enough to
make the expression levels more conducive for identification. Another possible reason this could
have occurred was due to degradation of some of the saliva samples, which could have resulted
in the large expression range. More research, however, needs to be done to determine if these are
viable options.
Additionally, body fluids can be subjected to different experimental conditions to determine
if the miRNA expression changes. For example, a time study could be performed to see if
miRNA expression is truly stable over time. Additionally, body fluids could be subjected to
different environmental conditions like sunlight exposure or extreme cold to determine if
miRNA expression remains stable throughout these changes. Throughout each of these
experiments, more samples should be used and the samples should be from a diverse set of
people. This would allow for the results to be trusted when being applied to a larger population
and many different demographic groups.
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Overall, more research needs to be done to assess the expression levels of miRNAs in each
body fluids over a wide range of environmental conditions, demographics, and time periods to
ensure that they can be reliably used in many different situations. Ultimately, any panel of
miRNAs that are chosen for body fluid identification will be used within forensic investigations.
Because the nature for forensic investigations is unpredictable, the expression levels of the
miRNAs need to be studied extensively so they can be reliably used for forensic purposes.
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7.1

Chapter 7: Appendices
Appendix A – miRNeasy Extraction Protocol
This protocol was used for all samples. As stated before, liquid samples were extracted

using 500 uL. For samples collected via sterile swabs, the swab head was removed and extracted
was performed on the swab head.
Place sample in 700 uL QIAzol Lysis Reagent. Vortex or pipet to mix. Incubate sample
at room temp for five minutes. Add 140 uL chloroform to the tube containing sample and shake
vigorously for fifteen seconds. Incubate sample at room temperature for 2-3 minutes. Centrifuge
sample for fifteen minutes (12,000 x g at 4˚C). Transfer the upper aqueous layer to a new
collection tube. Add 1.5 volumes of 100% ethanol and mix thoroughly by pipetting up and down
several times. Do not centrifuge the sample at this time. Pipet up to 700 uL of the sample,
including any precipitate that formed into spin column in a 2 mL collection tube. Centrifuge for
15 seconds (≥ 8000 x g at room temperature). Discard flow through. Repeat this step using the
remainder of the sample. Pipet 350 uL of Buffer RWI into the spin column and centrifuge for 15
seconds at ≥ 8000 x g. Discard the flow through. At this time, prepare the DNase solution by
pipetting 10 uL DNase stock solution to 70 uL of Buffer RDD. Mix gently by inverting tube and
centrifuge briefly to collect residual liquids from side of tube. Add the 80 uL of prepared DNase
solution to the spin column and incubate at room temperature for fifteen minutes. Add 350 uL of
RWI to the spin column. Centrifuge for 15 seconds at ≥ 8000 x g. Discard the flow through.
Pipet 500 uL of RPE into the spin column. Centrifuge for 15 seconds at ≥ 8000 x g to wash
column. Discard the flow through. Add another 500 uL of RPE into column and centrifuge for
two minutes at ≥ 8000 x g to dry the column. Discard the flow through. Place the spin column
into new 2 mL collection tube and discard old collection tube with flow through. Centrifuge in a
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microcentrifuge at full speed for one minute. Transfer RNeasy spin column to a new 1.5 mL
collection tube. Pipet 30-50 uL RNase-free water directly onto RNeasy spin column membrane.
Centrifuge for one minute at ≥ 8000 x g to elute the RNA.
The samples were then stored at -20˚C in an area that was isolated from the collected
samples until further use.

7.2

Appendix B – Qubit 3 Fluorometer
For optimal results, all reagents must be stored at room temperature. Additionally, the

sample preparation and testing should be done at room temperature as well. After the samples are
prepared, they are only stable for three hours and must be tested within that time frame.
First, one must prepare the samples for testing. Set up the required number of 0.5 mL
tubes for the number of samples and standards being used, keeping in mind that the Qubit RNA
HS Assay has 2 standards. It’s important to note that only thin-walled, clear tubes can be used.
Prepare the working solution by diluting the HS Reagent 1:200 in the HS Buffer. Add 190 µL of
the working solution into each of the tubes used for standards. Add 10 µL of each standard into
the appropriate tube and vortex for 2-3 seconds. Add 199 µL of the working solution to the tubes
for the samples. Add 1 µL of the samples to the appropriate tubes and vortex for 2-3 seconds. Let
the mixtures within the tubes at room temperatures for 2 minutes.
After the incubation period has ended, it is necessary to set the Qubit 3.0 Fluorometer for
reading standards and samples. On the home screen, choose “RNA” and then select the assay
type by choosing “RNA: High Sensitivity”. Choose “Read Standard” to continue on to
processing the standards. Insert the tube containing Standard 1 into the sample chamber, close
the lid, and then choose “Read Standard”. The reading will be complete in approximately three
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seconds. Repeat these steps with the tube containing Standard 2. After the second standard is
read, the instrument should show calibration results. If the calibration results are within the
guidelines, the samples can be processed.
When the samples are ready to be read, choose “Run Samples” and select the sample
volume added to the working solution and the unit of measurement preferred. Insert a sample
tube into the sample chamber, close the lid, and then choose “Read tube”. The concentration of
the sample will be displayed on the screen. Repeat these steps until all of the samples have been
read.

7.3

Appendix C – 2100 Bioanalyzer Small RNA Kit
Before preparing samples for the 2100 Bioanalyzer and the Small RNA Kit, the chip

priming station and reagents should be prepared. Regarding the chip priming station, the base
plate should be placed into position C. Regarding the syringe clip, the lever must be placed in the
lowest possible position. The kit reagents must be kept at 4˚C, apart from the Small RNA Ladder
which should be kept at -70˚C. It is important to use a new syringe and new electrode cleaners
with every new kit being used. Regular maintenance should also be performed on the 2100
Bioanalyzer, including cleaning the electrodes before and after sample runs.
When the samples are ready to be prepared for running, take them out and allow them to
thaw on ice. The Small RNA Ladder should also be taken out of -70˚C and thawed on ice. The
kit reagents should be taken out of the 4˚C and allow to equilibrate at room temperature for at
least thirty minutes. The complete volume of the Small RNA gel matrix should be transferred to
the top of the spin filter. The spin filter should be centrifuged for fifteen minutes at room
temperature at 10,000 g ±. After centrifugation, the filter can be removed and the gel is ready for
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sample preparation. It will be used for the preparation of the gel-dye mix. Vortex the Small RNA
dye concentrate for approximately ten seconds. Pipette 2 µL of the prepared die into a 0.5 mL
microcentrifuge tube that is RNase free. Add 40 µL of the previously prepared Small RNA gel
matrix and mix the solution bey pipetting. The mixture should be spun in a microcentrifuge at
13,000 g for ten minutes at room temperature.
After the gel-dye mix has been centrifuged, it needs to equilibrate to room temperature
for thirty minutes before being loaded into the Small RNA chip. Place a Small RNA chip on the
chip priming station and slowly pipette 9.0 µL of the gel-dye mix into the well that is marked
with a bold “G”. Lock the latch of the chip priming station and press the plunger of the syringe
all the way down. Allow the plunger to stay in this position for 60 seconds and then release the
plunger. Pipette 9.0 µL of the gel-dye mix into the two well marked with a non-bold “G”. Pipette
9 µL of the Small RNA conditioning solution into the well that is marked with “CS”. Pipette 5
µL of the Small RNA marker into the well that is marked with a ladder symbol and each of the
eleven sample wells. Pipette 1 µL of the Small RNA Ladder into the well that is marked with the
ladder symbol. Pipette 1 µL of each sample into each of the sample wells. If well is not being
used for a sample, 1 µL of the Small RNA maker or RNase free water can be utilized. Vortex the
chip for 60 seconds at 2400 rpm in an IKA vortex mixer. After the chip has been vortexed, it
must be placed into the 2100 Bioanalyzer and processing must commence within five minutes.
Open the 2100 Bioanalyzer software and place the chip within the electrode slot within
the 2100 Bioanalyzer. Choose the “Instrument” tab and choose the Small RNA assay in the
“Assays” folder. Fill in any sample information in the table that is provided. When ready, choose
“Start” to start the run. Allow the assay to run and the data can be obtained in the “Data” tab.
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7.4

Appendix D – 2100 Bioanalyzer RNA 6000 Nano Kit
Like with the Small RNA Kit, the chip priming station and reagents for the RNA 6000

Nano Kit must be prepared before samples can be prepared. Regarding the base plate of the chip
priming station, the base should be placed in position C. Regarding the syringe clip of the chip
priming station, the lever of the clip should be in the top most position. The kit reagents must be
kept at 4˚C, apart from the RNA Ladder which should be kept at -70˚C. It is important to use a
new syringe and new electrode cleaners with every new kit being used. Regular maintenance
should also be performed on the 2100 Bioanalyzer, including cleaning the electrodes before and
after sample runs.
Before samples can be prepared, the gel-dye mix must be made. All reagents must be
taken out of storage and allowed to equilibrate to room temperature for at least half an hour. The
RNA Ladder, however, needs to be thawed on ice. Place 550 µL of the RNA 6000 Nano gel
matrix into the top of the provided spin filter and centrifuge the spin filter for ten minutes at
1,500 g ± 20%. Aliquot 65 µL of the filtered gel into a 05 mL microcentrifuge tube that is
RNase-free. Vortex the RNA 6000 Nano dye concentrate for approximately ten seconds. At 1 µL
of RNA 6000 Nano dye concentrate to the 65 µL aliquot of the filtered gel. Vortex the mixture
and then centrifuge the mixture for ten minutes at room temperature at 13,000 g.
After the gel-dye mixture is done being centrifuged, it must be allowed to equilibrate to
room temperature for approximately thirty minutes. The gel-dye mixture must be protected from
light during this time as well. Place a new RNA Nano chip on the chip priming station and
pipette 9.0 µL of the gel-dye mixture in the well that is marked the a bold “G”. Close the chip
priming station and push the plunger all the way down. Allow the plunger to stay in that position
for thirty seconds and then release. Pipette 9.0 µL of the gel-dye mixture into the two wells that
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are marked with the non-bolded “G”. Pipette 5 µL of the RNA 6000 Nano marker into the well
that is marked with the ladder symbol and in each of the 12 sample wells. Pipette 1 µL of the
RNA ladder into the well that is marked with the ladder symbol. Pipette 1 µL of each of the
samples into each of the 12 sample wells. Place the prepared chip in the IKA vortex mixer the
vortex the chip for sixty seconds at 2400 rpm. Once this is complete, the processing of the chip
must start within five minutes.
Open the 2100 Bioanalyzer software and place the chip within the electrode slot within
the 2100 Bioanalyzer. Choose the “Instrument” tab and choose the RNA Nano 6000 assay in the
“Assays” folder. Fill in any sample information in the table that is provided. When ready, choose
“Start” to start the run. Allow the assay to run and the data can be obtained in the “Data” tab.

7.5
7.5.1

Appendix E – Day 1 of TruSeq Small RNA Protocol
Ligate Adapters
Thaw all consumables (10 mM ATP, HML, RA3, RA5, RNase inhibitor, STP, T4 RNA

Ligase, Ultrapure water, T4 RNA Ligase 2/Deletion Mutant) on ice. Centrifuge each consumable
at 600 x g for five seconds and set aside on ice.
Take out samples being sequenced and thaw on ice. Once thawed, prepare the samples
appropriately in order to get 1 µg of total RNA in 5 µL of Nuclease Free water. Combine the 5
µL of sample with 1 µL of RA3. Pipette to mix and then centrifuge briefly. Place prepared
samples on a thermal cycler preheated to 70˚C. Incubate for 2 minutes. Remove the samples
from the thermo cycler and place on ice. Preheat the thermo cycler to 28˚C. In a new 200 µL
PCR tube, combine the following volumes on ice (multiply each volume by the number of
samples being prepared):
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•

HML (2 µL)

•

RNase Inhibitor (2 µL)

•

T4 RNA Ligase 2, Deletion Mutant (1 µL)

Pipette to mix and centrifuge briefly. Add 4 µL of the mixture to the tubes of RA3/total RNA
mixture and pipetted to mix. Place these samples on the thermocycler preheated to 28˚C and
incubate for 1 hour. After 1 hour, add 1 µL of STP and pipette to mix. Return samples to thermo
cycler and continue incubating at 28˚C for 15 minutes. At the end of 15 minutes, remove the
samples from the thermal cycler and place on ice. At this time, the 3’ Adapters have been ligated.
Next, the 5’ Adapters need to be ligated. Preheat the thermo cycler to 70˚C. Add 1.1 x N
µL (where N = number of samples) RA% to a new 200 µL PCR tube. Place this tube on the
preheated thermo cycler and incubate for 2 minutes. Remove this tube from the thermocycler and
place on ice. Preheat the thermo cycler to 28˚C. Add 1.1 x N µL 10 mM ATP to the tube of RA5
and pipette to mix. Add 1.1 x N µL T4 RNA Ligase to the RA5/ATP mixture and pipette to mix.
Add 3 µL of this mixture to the tube containing the RA3 mixture and pipette to mix. Place the
prepared samples on the preheated thermo cycler and incubate at 28˚C for one hour. After an
hour passes, remove the samples from the thermal cycler and place on ice.

7.5.2

Reverse Transcribe and Amplify Libraries

7.5.2.1 Preparation
Thaw all consumables (25 mM dNTP mix), PML, RPI, RNA PCR Primer Indices, RTP,
RNase Inhibitor, ultrapure water, 5X First Strand Buffer, 100 mM DTT, High Sensitivity DNA
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chip, SuperScript II Reverse Transcriptase) on ice. Centrifuge all consumables at 600 x g for five
seconds and set aside on ice. Preheat the thermocycler to 70˚C.
7.5.2.2 Dilute 25 mM dNTP Mix
Combine the following volumes in a new 200 µL PCR tube labeled 12.5 mM dNTP Mix.
Make sure to multiply each volume by the number of samples being prepared and prepare 10%
extra.
•

25 mM dNTP Mix (0.5 µL)

•

Ultrapure Water (0.5 µL)

Pipette to mix and set aside on ice.
7.5.2.3 Reverse Transcription
Add 6 µL of each adapter-ligated RNA library to new 200 µL PCR tubes. Add 1 µL RNA
RT Primer to the tube of adapter-ligated RNA at pipette to mix. Centrifuge the mixture briefly.
Place the tubes on the preheated thermo cycler and incubate at 70˚C for 2 minutes. After 2
minutes, remove from the thermo cycler and place on ice. Preheat the thermo cycler to 50˚C.
Combine the following volumes of reagents in a new 200 µL PCR tube on ice, making sure to
multiply each volume by the number of libraries (samples) being prepared. Make 10% extra
reagent.
•

5X First Strand Buffer (2 µL)

•

12.5 mM dNTP Mix (0.5 µL)

•

100 mM DTT (1µL)

•

RNase Inhibitor (1 µL)

•

SuperScript II Reverse Transcriptase (1 µL)
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Pipette to mix and then centrifuge briefly. Add 5.5 µL of this mixture to the tube of the adapter
ligated RNA/primer mix and pipette briefly. Centrifuge this mixture briefly. Place the samples
on the preheated thermocycler and incubate at 50˚C for 1 hour. After 1 hour, remove the samples
from the thermal cycler and place on ice.

7.5.3

Amplify Libraries
Combine the following reagents in a new 200 µL PCR tube on ice, making sure to

multiply each volume by the number of libraries (samples) being prepared. Make 10% extra
reagent. This is the PCR master mix.
•

Ultrapure water (8.5 µL)

•

PML (25 µL)

•

RP1 (2 µL)

Pipette to mix and centrifuge briefly. Add 35.7 µL of the Master Mix to the adapter-ligated RNA
mixture tubes. Pipette to mix. Add 2 µL of a pre-determined RPIX to each mixture. Each
different tube/sample should get a different RPIX. Pipette to mix and then centrifuge briefly.
Incubate the samples in a thermocycler using the following program.
•

Choose the preheat lid option and set to 100˚C

•

98˚C for 30 seconds

•

11-15 cycles of:
o 98˚C for 10 seconds
o 60˚C for 15 seconds
o 72˚C for 10 minutes
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o 4˚C hold
Run each library (sample) on a High Sensitivity DNA chip (as seen in Appendices F).
This is a safe stopping point. The tubes can be capped and stored at -25˚C to -15˚C for up to 7
days.

7.6

Appendix F – 2100 Bioanalyzer DNA 1000 Chip Kit
Like with the Small RNA Kit and RNA 6000 Nano Kit, the chip priming station and

reagents for the DNA 1000 Chip Kit must be prepared before samples can be prepared.
Regarding the base plate of the chip priming station, the base should be placed in position C.
Regarding the syringe clip of the chip priming station, the lever of the clip should be in the top
most position. syringe clip of the chip priming station, the lever of the clip should be in the top
most position. The kit reagents must be kept at 4˚C. It is important to use a new syringe and new
electrode cleaners with every new kit being used. Regular maintenance should also be performed
on the 2100 Bioanalyzer, including cleaning the electrodes before and after sample runs.
First, all of the kit reagents must be taken out of 4˚C storage and allowed to equilibrate to
room temperature for at least 30 minutes. Vortex the blue-caped DNA dye concentrate for 10
seconds and centrifuge briefly. Pipette 15 µL of the dye concentrate into the red-capped DNA
gel matrix vial. Vortex for 10 seconds to properly mix the two components. Transfer the gel-dye
mix to the top receptacle of a spin filer and place the spin filter into a microcentrifuge and
centrifuge for `5 minutes at room temperature at 1400 g ± 20%. After centrifugation, discard the
filter according to good laboratory practices and label the gel-dye mixture with the date of
preparation. The prepared gel-dye mix must be used within 4 weeks of preparation.
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7.7
7.7.1

Appendix G – Day 2 of TruSeq Small RNA Protocol
Preparing Consumables
Thaw all consumables on ice and centrifuge at 600 x g for five seconds and then set the

consumables aside on ice. The consumables include the Custom RNA Ladder (CRL), High
Resolution Ladder (HRL), 5 µm filter tubes, amplified cDNA construct, DNA loading dye, 3 M
NaOAc (pH 5.2), 10 mM Tris-HCL (pH 8.5), and ethanol. Additionally, set aside the following
consumables: gel breaker tubes, High Sensitivity DNA Kit, Novex TBE gels (6%, 10 wells),
Novex TBE running buffer (5x), nuclease-free 200 µL PCR tubes, nuclease-free 1.5 mL
microcentrifuge tubes, a razor blade, ultrapure ethidium bromide (0.5 µL/mL in water), and
100% ethanol.

7.7.2

Preparing Running Buffer and Electrophoresis Chamber
Dilute the 5x Novex TBE Running Buffer to a concentration of 1x. Approximately 800-

1000 µL of the 1x running buffer will be needed for the running of the gel. Place the 6% Novex
TBE gel into the gel electrophoresis chamber (Novex SureLock System) per manufacturer
instructions. Fill the running chamber with the running buffer until the 6% Novex TBE gel is
fully covered.

7.7.3

Run Gel Electrophoresis
Combine 2 µL of the CRL with 2 µL DNA loading dye in a new 200 µL PCR tube and

pipette to mix. Combine 2 µL of the HRL and 2 µL DNA loading dye in a new 200 µL PCR and
pipette to mix.
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Combine all amplified cDNA content (48-50 µL per sample) and 10 µL of DNA loading
dye in a 1.5 microcentrifuge tube. Pipette to mix thoroughly. Load 2 gel lanes with the 2 µL
HRL mixture in the two most outer lanes. Load 2 gel lanes with 2 µL CRL mixture into the lanes
next to the HRL (moving toward the middle of the gel). Load 2 gel lanes with 25 µL of the
amplified cDNA content mixture into the middle lanes of the gel. Run the gel for 60 minutes at
145 V or until the dye front leaves the gel. Once the gel is finished running, remove the gel from
the unit.

7.7.4

Recover the Purified cDNA Construct from the Gel
Open the gel cassette carefully, making sure not to break the gel. Stain the gel with the

ethidium bromide in a clean container for two to three minutes. Properly dispose of the ethidium
bromide once the staining has completed.
Place a gel breaker tube into a 2.0 mL microcentrifuge tube. View the gel on a UV
transilluminator. Cut out the miRNA bands in the sample lanes using a razor blade. The bands
should be approximately at the 147 nt band region. Use the HRL and CRL bands to determine
the sizing of the sample bands to ensure that the correct miRNA bands are cut out. Place the cutout bands into the 0.5 mL gel breaker tube that is nested in the 2.0 mL microcentrifuge tube.
Centrifuge the nested tubes at 20,000 x g for 2 minutes. This allows the gel through the holes
into the 2 mL microcentrifuge tube. If one so chooses, the final library can be concentrated. If
this optional procedure is not done, add 200 µL of ultrapure water to the gel debris in the 2.0 mL
tube. Rotate or shake the tube for at least 2 hours to elute the DNA. Transfer the eluate and gel
debris to the top of the 5 µm filter and centrifuge at 10 seconds at 600 x g.
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7.7.5

Concentrate Final Library (Optional)
Add 300 µL ultrapure water to the gel debris in the 2.0 mL microcentrifuge tube. Rotate

or shake the microcentrifuge tube for at least 2 hours to elute the DNA. Transfer the eluate and
gel debris to the top of a 5 µm filter and centrifuge at 600 x g for 10 seconds. Discard the filter.
Add the following volumes to the eluate:
•

2 µL glycogen

•

30 µL 3M NaOAc

•

975 µL 100% ethanol

•

2 µL 0.1 X Pellet Paint (optional)

Pipette to mix thoroughly. Centrifuge at 20,000 x g on a benchtop microcentrifuge at 20
minutes at 4˚C. Remove and discard the supernatant and leave the pellet intact. If the pellet
becomes loose, centrifuge at 20,000 x g for 2 minutes to re-create the pellet. Wash the pellet with
500 µL of 70% ethanol. Centrifuge at 20,000 x g for 2 minutes. Remove and discard the
supernatant, leaving the pellet intact. Place the microcentrifuge tube with the lid open in a 37˚C
heat block until the pellet is dry (approximately 7 minutes). Resuspend the pellet in 10 µL of 10
mM Tris-HCl, pH 8.5.

7.7.6

Check Libraries
Load 1 µL of the purified library/sample onto an Agilent Technologies 2100 Bioanalyzer

using a DNA-specific chip, such as the DNA 1000 or High Sensitivity DNA. The current study
used a DNA 1000 chip/kit and instructions can be found in Appendices F.
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Check the size, purity, and concentration of the library. For clustering, use the total of all
molarities from the results. For example, if there are three peaks, add the molarity of each of the
peaks to determine the overall molarity.

7.7.7

Normalize Libraries

Normalize the library concentration to 2 nM using Tris-HCl 10mM, pH 8.5. This is a safe
stopping point. Cap the tube and store at -25˚C to -15˚C for up to 7 days.

7.8
7.8.1

Appendix H – Day 3 of TruSeq Small RNA Protocol
Prepare the Reagent Cartridge
Remove the reagent cartridge from -25˚C to -15˚C storage and place the reagent cartridge

in a water bath of room temperature deionized water. Ensure that the water does not go above the
marked line on the reagent cartridge. Allow the reagent cartridge to thaw in the room
temperature water for approximately 60-90 minutes or until the liquid within the cartridge is
thawed completely. Remove the cartridge from the water bath and tap it on a bench. This
dislodges water from the base of the cartridge. The cartridge base should be dried and no water
should be left on the top of the reagent cartridge. Invert the reagent cartridge ten times to mix the
reagents and then visually ensure that all of the reagents are thawed completely. Visually ensure
that the reagents in positions 1, 2, and 4 are fully mixed and contain no precipitates. Place the
reagent cartridge on ice or store it at 2˚C to 8˚C until ready to set up a run.
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7.8.2

Load Sample Reagents into Reagent Cartridge
Use a low-lint lab tissue to clean the foil seal that is covering the “Load Samples”

reservoir. Use a clean 1 mL pipette tip to pierce the foil seal that is covering the “Load Samples”
reservoir. Pipette 600 µL of the prepared sample libraries into the “Load Samples” reservoir,
making sure not to touch the foil seal as the sample is dispensed. If air bubbles are present,
gently tap the cartridge on the bench to release the bubbles.

7.8.3

Run Samples on MiSeq FGx

Log into the MiSeq FGx with the proper credentials. From the welcome screen, select
“Sequence” and then select “Research Use Only Run” when asked to select run type. Follow the
prompts to load the flow cell and the reagents in order to set up the run.
The flow cell is immersed in a storage buffer in a flow cell container and must be
removed and cleaned. Using gloves, grip the base of the plastic cartridge with plastic forceps and
remove it from the flow cell container. Rinse the flow cell with nuclease-free water. Both the
glass and plastic cartridge are thoroughly rinsed. Dry the flow cell and cartridge using a lint-free
lens cleaning tissue, making sure to pat dry the area of the gasket and the adjacent glass. Clean
the flow cell glass using an alcohol wipe or ethanol. Visually inspect the glass to make sure it is
free of streaks, fingerprints, and lint. Dry any excess alcohol with a lint-free lens cleaning tissue.
To load the flow cell into the instrument, raise the flow cell compartment door and press the
release button to the right of the flow cell latch to open it. Ensure that the flow cell stage is free
of lint or other debris. Place the flow cell on the flow cell stage and gently press down on the
flow cell latch to close it over the flow cell. Close the flow cell compartment door and then click
Next on the instrument’s screen.
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Remove the bottle of SBS solution (PR2) from 2˚C to 8˚C storage and gently invert the
bottle to mix the solution. Remove the lid from the bottle. Open the reagent compartment door
and raise the sipper handle until it locks in place. Place the SBS solution bottle in the indentation
to the right of the reagent chiller. Ensure that the waste bottle is empty. Lower the sipper handle
slowly into the SBS solution. Select Next on the instruments’ screen.
Open the reagent chiller door. Hold the reagent cartridge on the end with the Illumina
label (there is a handle on that side) and slide the reagent cartridge into the reagent chiller until it
is fitted into the instrument. Close the reagent chiller door and then close the compartment door.
Select Next on the instrument’s screen.
Load the appropriate sample sheet and ensure that the worklist name, analysis workflow,
and read length are correct. A pre-run check will be performed. Wait until this is complete and
then select “Start Run”. While the instrument is running, the progress can be monitored.
7.9

Appendix I – Quantification Raw Data
Table 6: Quantification Raw Data

Sample

Nanodrop
Conc.
(ng/uL)

Quibit 3
Conc.
(ng/uL)

1

6.8

2

4.8

3

6.4

4

5.7

5

23.7

out of
range (too
low)
out of
range (too
low)
out of
range (too
low)
out of
range (too
low)
18.8

2100 Bioanalyzer RNA
6000 Nano Kit
RNA
RIN
Conc.
(ng/uL)
2
NA

2100 Bioanalyzer Small RNA Kit
Small RNA
Conc.
(ng/uL)
6.4873

miRNA
Conc.
(ng/uL)
2.3645

%
miRNA
(%)
36

3

NA

4.8766

1.5806

32

1

NA

8.1917

3.3584

41

4

NA

4.1155

0.9282

23

13

4.9

19.3239

6.2536

32

82

6
7
9
10
11
12
13

69
33.2
18
12.6
161.9
38.2
54

71.8
28.4
13.4
7.27
180
2.85
55.4

34
15
9
6
87
NA
30

3.4
5.8
NA
NA
2.5
NA
2.1

70.1771
19.7044
14.8675
12.2604
170.2607
NA
434.0601

29
14
15
21
38
NA
45

4.9274
NA
681.7783
5.4764
22.349
13.1301
94.9288
2.5854

20.6854
2.8303
2.2461
2.5645
64.7692
NA
195.468
8
3.5204
NA
355.316
3.764
10.3997
7.0153
44.0502
1.3397

14
15
16
18
21
22
23
24

7.4
124.4
60.9
8
37.6
19.5
307.9
5.2

6
NA
46
7
26
15
403
3

NA
NA
2.4
NA
4.9
1.2
2.5
NA

25
26
28

317.1
7.2
2.7

392
3
2

29
30

23.9
1.8

32
66
046A
046B
046C
047A
047B
047C
048A

81.6
41.6
48.7
162.7
25.7
12.4
61.4
120.4
215

6.58
80
64
7.2
43.4
25.2
318
out of
range (too
low)
360
5.58
out of
range (too
low)
25.6
out of
range (too
low)
76.2
49
47.4
160
31.4
10.1
46.6
91.6
216

2.6
NA
NA

40.4944
4.4362
1.2057

19.7728
1.8467
0.4256

49
42
35

21
3

1.5
NA

31.8625
0.6092

15.5918
0.285

49
47

65
22
28
123
22
6
29
92
248

3.5
2.3
1.9
2.9
3
NA
3.9
5.5
4.1

13.4182
30.3993
16.439
12.7216
730.3137
8.9582
10.8808
NA
2294.012

44
55
55
59
5
45
64
NA
27

300
385

549
319

4.1
3.8

33.0115
2060.285

5.32
14.8
64.2
112

3
8
3
94

NA
NA
NA
2.8

3.2389
4.2941
2.5545
444.9739

5.9051
16.8577
9.0877
7.5229
36.8845
4.0692
6.9785
NA
615.206
9
15.0418
546.815
6
1.3601
2.3676
1.2816
189.894
6

048B
048C

456
409.8

051A
051B
051C
052A

9.3
21.8
6.4
105

83

71
NA
52
68
47
53
46
52

46
27
42
55
50
43

052B
052C
053A
053B
053C
054A
054B
054C

90.8
59.3
78.7
29.2
54.8
135.4
228.2
124.2

92.6
63.6
80.4
27.4
57.6
128
157.2
116

44
32
60
16
36
104
155
75

2.1
1.5
6.4
7.1
6.8
5.4
3.1
6.1

20.1176
21.7038
21.9673
12.434
16.9728
15.1064
97.2388
1569.583

055A
055B

142.2

134
104

200
78

6.3
4.8

27.5086
1164.185

055C
068A

22.3
237.2

18.7
148

9
132

NA
3.5

13.4845
796.6704

068B
068C
056A
056B
056C
057A
057B
057C

166.8
101.6
154
75.6
149.5
190
34.7
28.3

134
90.6
136.4
64.8
158
188
10.5
28

135
80
96
43
74
208
6
417

6.5
5.6
3.3
2.7
2.8
3.9
NA
2.8

10.7397
8.5031
13.2023
12.6614
15.0189
17.8175
6.5182
999.5266

058A
058B

239.7
354.6

200
356

222
179

2.6
2.8

20.4912
4660.195

058C

84.5

152
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2.8

1061.699

060A
060B
060C
061A
061B
061C

49
9.4
47.6
236.7
232.6
310

55.4
82.8
56
291
200
350.4

34
6
30
225
148
423

8.1
NA
7.8
4.4
5.5
5.7

11.008
6.3077
9.9987
1526.636
19.1369
1217.632

062A

416.3

399

58

4.4

254.6584

062B
062C
063A

320.1
628.8
271.3

386
397
310

5.6
5.9
2.8

3511.156
2420.294
2358.337

063B
063C

285.2
223.3

375.2
574.4
out of
range (too
low)
221.4
207
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133

4.2
2.9

2036.866
2018.678

84

8.7834
10.689
10.7679
6.3014
8.6363
7.8462
1.1383
515.148
3
11.5487
320.106
3
5.3348
206.228
2
5.9621
4.3395
6.6022
5.5767
6.9614
10.0118
3.4726
273.659
5
9.2986
1227.42
3
160.060
7
6.861
3.3912
5.9162
304.748
7.2987
201.866
5
109.404
2
525.811
40.0086
150.532
2

44
49
49
51
51
52
1
33

90.3311
225.259

4
11

42
27
40
26
56
51
50
44
46
56
53
27
45
26
15
62
54
59
20
38
17
43
15
2
6

064A
064B

166.8
279.8

160
174

88
116

2.6
2.9

20.9915
1505.714

064C
065A

181.9
841.9

166
728

113
609

4
3.1

11.0752
1623.173

065B
065C
069A
069B
069C

1870.5
1218
863.2
787.7
616.9

1140
2955
818
1010
744

1704
754
688
876
662

2.7
2.7
3.4
2.8
3.4

5136.211
29.4481
813.8969
3519.86
2391.162

7.10 Appendix J – Raw Data from RT-qPCR
7.10.1 Ct Values and ΔCt Values for miR-451
Table 7: miR-451 Ct Value Data
Sample
1
4
6
9
10
12
13
15
16
18
22
23
29
32
66
47C
53A
54C
55A
68B
57A
61C
62C

miR-16
14.12
15.717
14.023
14.196
16.091
31.8
20.62
20.146
24.305
24.486
26.323
34.267
23.08
31.388
27.252
15.28
17.343
17.358
14.529
16.022
24.344
24.412
23.78

miR-451
15.468
16.912
16.778
15.692
16.445
38.054
32.004
29.02
37.316
30.196
32.039
36.462
36.101
32.376
32.155
18.204
21.199
26.178
19.288
18.547
36.607
37.466
38.481

85

Δ Ct
1.348
1.195
2.755
1.496
0.354
6.254
11.384
8.874
13.011
5.71
5.716
2.195
13.021
0.988
4.903
2.924
3.856
8.82
4.759
2.525
12.263
13.054
14.701

13.5142
492.109
7
6.7715
238.266
9
11.7639
10.557
95.664
373.816
266.196
3

64
33
6
15
0
36
12
1
11

63B
69C

22.424
23.232

38.553
37.047

16.129
13.815

7.10.2 Ct Values and ΔCt Values for miR-412
Table 8: miR-412 Ct Value Data
Sample
1
2
4
6
10
12
15
16
22
23
29
32
66
47C
53A
54C
55A
68B
57A
61C
62C
63B
69C

miR-16
14.12
14.57
15.717
14.023
16.091
31.8
20.146
24.305
26.323
34.267
23.08
31.388
27.252
15.28
17.343
17.358
14.529
16.022
24.344
24.412
23.78
22.424
23.232

miR-412
38.552
37.115
40
34.274
36.109
33.089
33.695
36.138
36.536
36.905
40
33.1
36.764
36.472
35.184
36.684
35.881
35.702
37.207
35.532
36.583
34.614
38.721

Δ Ct
24.432
22.545
24.283
20.251
20.018
1.289
13.549
11.833
10.213
2.638
16.92
1.712
9.512
21.192
17.841
19.326
21.352
19.68
12.863
11.12
12.803
12.19
15.489

7.10.3 Ct Values and ΔCt Values for miR-891a
Table 9: miR-891a Ct Value Data
Sample
1
4
6
9

miR-16
14.12
15.717
14.023
14.196

miR-891a
37.81
37.101
34.878
40
86

Δ Ct
23.69
21.384
20.855
25.804

10
12
13
14
15
16
18
22
23
29
32
66
47C
53A
54C
55A
68B
57A
61C
62C
69C

16.091
31.8
20.62
22.183
20.146
24.305
24.486
26.323
34.267
23.08
31.388
27.252
15.28
17.343
17.358
14.529
16.022
24.344
24.412
23.78
23.232

37.526
26.549
27.489
25.318
23.755
22.887
24.317
38.866
38.311
38.872
37.465
40
39.518
40
40
40
37.057
38.607
40
40
37.864

21.435
-5.251
6.869
3.135
3.609
-1.418
-0.169
12.543
4.044
15.792
6.077
12.748
24.238
22.657
22.642
25.471
21.035
14.263
15.588
16.22
14.632

7.10.4 Ct Values and ΔCt Values for miR-205
Table 10: miR-205 Ct Value Data
Sample

miR-16

miR-205

Δ Ct

4

15.717

40

24.283

5

16.02

40

23.98

6

14.023

40

25.977

9

14.196

40

25.804

10

16.091

40

23.909

12
13
14
15
16
18

31.8
20.62
22.183
20.146
24.305
24.486

29.06
25.385
25.759
24.515
25.157
26.09

-2.74
4.765
3.576
4.369
0.852
1.604

87

22
23
29
32
66
47C
53A
54C
55A
68B
57A
61C
62C
63B
69C

26.323
34.267
23.08
31.388
27.252
15.28
17.343
17.358
14.529
16.022
24.344
24.412
23.78
22.424
23.232

27.625
30.32
25.69
23.789
26.59
23.598
20.866
22.074
19.176
20.539
22.195
27.376
27.169
26.217
24.348

88

1.302
-3.947
2.61
-7.599
-0.662
8.318
3.523
4.716
4.647
4.517
-2.149
2.964
3.389
3.793
1.116
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